Ambu A/S (AMBFF)
OTCMKTS · Delayed Price · Currency is USD
13.65
+0.45 (3.41%)
At close: Feb 6, 2026
Ambu A/S Revenue
Ambu A/S had revenue of 1.56B DKK in the quarter ending December 31, 2025, with 3.18% growth. This brings the company's revenue in the last twelve months to 6.09B, up 7.76% year-over-year. In the fiscal year ending September 30, 2025, Ambu A/S had annual revenue of 6.04B with 11.98% growth.
Revenue (ttm)
6.09B DKK
Revenue Growth
+7.76%
P/S Ratio
3.64
Revenue / Employee
1.17M DKK
Employees
5,200
Market Cap
3.48B USD
Revenue Chart
* This company reports financials in DKK.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Sep 30, 2025 | 6.04B | 646.00M | 11.98% |
| Sep 30, 2024 | 5.39B | 616.00M | 12.90% |
| Sep 30, 2023 | 4.78B | 331.00M | 7.45% |
| Sep 30, 2022 | 4.44B | 431.00M | 10.74% |
| Sep 30, 2021 | 4.01B | 446.00M | 12.50% |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Zomedica | 29.45M |
| OpGen | 9.00M |
| Tian'an Technology Group | 2.12M |
| PetVivo Holdings | 1.41M |
| Positron | 486.45K |
| Guided Therapeutics | 178.00K |
| CS Diagnostics | 98.73K |
| Vivos | 48.62K |
Ambu A/S News
- 4 weeks ago - Ambu A/S (AMBBY) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow - Seeking Alpha
- 4 weeks ago - Ambu A/S (AMBBY) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 2 months ago - Ambu A/S Annual Shareholders Meeting Transcript - GuruFocus
- 2 months ago - Ambu A/S (AMBBY) Shareholder/Analyst Call Prepared Remarks Transcript - Seeking Alpha
- 2 months ago - Elastomeric Infusion Pumps Market worth $1.49 billion by 2030, at a CAGR of 5.3%, says MarketsandMarkets™ - Benzinga
- 3 months ago - Ambu A/S (AMBBY) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 4 months ago - Ambu A/S (AMBBY) Analyst/Investor Day - Slideshow - Seeking Alpha
- 1 year ago - Ambu AS (AMBFF) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic Innovations - GuruFocus